Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1) (2022)

Peer-Reviewed Study · Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators · April 30, 2022

Fizazi K et al., 2022-04-30: PEACE-1 used a 2×2 factorial design in 1,173 men with de novo metastatic disease; adding abiraterone to ADT with or without docetaxel improved radiographic progression-free survival and overall survival, with grade 3+ adverse events in 63% vs 52% of the docetaxel subgroup.

In the androgen deprivation therapy with docetaxel population (n=355 in both with abiraterone and without abiraterone groups), the HRs were consistent (radiographic progression-free survival 0·50, 99·9% CI 0·34-0·71; p<0·0001; overall survival 0·75, 95·1% CI 0·59-0·95; p=0·017).

Abstract (FINDINGS)

Fizazi K et al., 2022-04-30: PEACE-1 used a 2×2 factorial design in 1,173 men with de novo metastatic disease; adding abiraterone to ADT with or without docetaxel improved radiographic progression-free survival and overall survival, with grade 3+ adverse events in 63% vs 52% of the docetaxel subgroup. Funder: 'FUNDING: Janssen-Cilag, Ipsen, Sanofi, and the French Government.' Conflicts: individual disclosures in the Lancet appendix, not in the abstract; several investigators report Janssen/Sanofi advisory roles. Maker: Janssen-Cilag (abiraterone/Zytiga); docetaxel in the standard-of-care arm is Sanofi's. Comparator: standard of care (ADT with or without docetaxel), open label. Study type: randomized trial.